Effectiveness of adjuvant trastuzumab in women with HER-2+ breast cancer in the SUS
The aim of this study was to evaluate the effectiveness in a real-world study of adjuvant trastuzumab in women with HER-2+ initial breast cancer in overall survival and recurrence-free survival. A retrospective cohort study was conducted with women who had HER-2+ breast cancer treated with trastuzumab from July 2012 to May 2017 and followed up until July 2021. The death rate was 2.62 per 100 persons/year, and the incidence rate of recurrence was 7.52 per 100 persons/year. The probability of survival at 8.7 years was 85.9%, while the probability of recurrence-free survival in the same period was 62.8%. The use of trastuzumab proved to be effective in the adjuvant treatment of breast cancer in a public health service in southern Brazil. Prognostic factors associated with worse overall survival or relapse did not influence the natural history of the disease, except locally advanced disease at the beginning of treatment. The data presented may prove to be useful in helping to make decisions about whether to use trastuzumab in the treatment of initial or locally advanced breast cancer in the Brazilian SUS.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Ciencia & saude coletiva - 28(2023), 6 vom: 26. Juni, Seite 1819-1830 |
| Sprache: |
Portugiesisch |
|---|
| Weiterer Titel: |
Efetividade do Trastuzumabe adjuvante em mulheres com câncer de mama HER-2+ no SUS |
|---|
| Beteiligte Personen: |
Batista, Joanna d'Arc Lyra [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal, Humanized |
|---|
| Anmerkungen: |
Date Completed 01.06.2023 Date Revised 01.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1590/1413-81232023286.15092022 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357572920 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357572920 | ||
| 003 | DE-627 | ||
| 005 | 20231226072901.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||por c | ||
| 024 | 7 | |a 10.1590/1413-81232023286.15092022 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1191.xml |
| 035 | |a (DE-627)NLM357572920 | ||
| 035 | |a (NLM)37255158 | ||
| 035 | |a (PII)S1413-81232023000601819 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a por | ||
| 100 | 1 | |a Batista, Joanna d'Arc Lyra |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effectiveness of adjuvant trastuzumab in women with HER-2+ breast cancer in the SUS |
| 246 | 3 | 3 | |a Efetividade do Trastuzumabe adjuvante em mulheres com câncer de mama HER-2+ no SUS |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.06.2023 | ||
| 500 | |a Date Revised 01.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The aim of this study was to evaluate the effectiveness in a real-world study of adjuvant trastuzumab in women with HER-2+ initial breast cancer in overall survival and recurrence-free survival. A retrospective cohort study was conducted with women who had HER-2+ breast cancer treated with trastuzumab from July 2012 to May 2017 and followed up until July 2021. The death rate was 2.62 per 100 persons/year, and the incidence rate of recurrence was 7.52 per 100 persons/year. The probability of survival at 8.7 years was 85.9%, while the probability of recurrence-free survival in the same period was 62.8%. The use of trastuzumab proved to be effective in the adjuvant treatment of breast cancer in a public health service in southern Brazil. Prognostic factors associated with worse overall survival or relapse did not influence the natural history of the disease, except locally advanced disease at the beginning of treatment. The data presented may prove to be useful in helping to make decisions about whether to use trastuzumab in the treatment of initial or locally advanced breast cancer in the Brazilian SUS | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Trastuzumab |2 NLM | |
| 650 | 7 | |a P188ANX8CK |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 700 | 1 | |a Alves, Rafael José Vargas |e verfasserin |4 aut | |
| 700 | 1 | |a Cardoso, Taís Belladona |e verfasserin |4 aut | |
| 700 | 1 | |a Moreno, Marcelo |e verfasserin |4 aut | |
| 700 | 1 | |a Tiscoski, Katsuki Arima |e verfasserin |4 aut | |
| 700 | 1 | |a Polanczyk, Carisi Anne |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Ciencia & saude coletiva |d 1998 |g 28(2023), 6 vom: 26. Juni, Seite 1819-1830 |w (DE-627)NLM096527056 |x 1678-4561 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2023 |g number:6 |g day:26 |g month:06 |g pages:1819-1830 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1590/1413-81232023286.15092022 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2023 |e 6 |b 26 |c 06 |h 1819-1830 | ||